INTS · Intensity Therapeutics, Inc.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027.

The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).

In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026.

On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.

The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).

In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026.

On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.

Granted to the Reporting Person as a fully vested stock award under the Issuer's 2021 Stock Incentive Plan in partial satisfaction of the 2025 bonus payment to the Reporting Person in lieu of cash, at the Reporting Person's request.

On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.

The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).

In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025.

The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).

In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025.

The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).

In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025.

The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).

In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025.

This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on May 2, 2025.

This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025.

This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on May 2, 2025.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025.

This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on May 2, 2025.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025.

This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on October 21, 2024.

This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on October 21, 2024.

This option is fully vested and exercisable as of March 27, 2021.

Due to an inadvertent error, the Form 3 filed by the Reporting Person on June 29, 2023 incorrectly reported the amount of securities beneficially owned. This inadvertent error caused the amount of securities beneficially owned to be understated by 691 shares. The new amount reported in Column 5 reports the correct amount of securities beneficially owned following the reported transaction.

This option will vest, subject to Mr. Dubin's continued service, in four equal annual installments beginning on May 14, 2024.

This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2025.

This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2024.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2024.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2024.

This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2024.

This option vested 100% on March 6, 2024.

This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four equal, annual installments, beginning on December 11, 2024.

This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., according to the following schedule: 25% will vest on July 19, 2023, and the remaining 75% will vest in three, equal, annual installments, beginning on July 19, 2024.